Symbol: TSX-V: LG
MONTREAL, April 27, 2018 /CNW Telbec/ - LGC Capital Ltd. (TSXV: LG) ("LGC") is pleased to announce it has been advised by Australian Medical Cannabis LP, Little Green Pharma, that it has completed its first Australian harvest this week.
LGC recently increased its strategic interest in Little Green Pharma to 14.99%.
Post manufacturing and subject to the strict Therapeutic Goods Order No. 93 mandatory testing, Little Green Pharma expects to have the first Australian grown Medicinal Cannabis products available for sale both domestically and internationally.
John McMullen, CEO of LGC commented, "This is a great milestone for Little Green Pharma and their team. This is one of the first crops grown and harvested in Australia and we look forward to their unique product offering."
Fleta Solomon, Little Green Pharma's Managing Director commented, "This is a great step towards the Company's vision of being one of the first companies in Australia to produce a high-quality, locally-grown medicine for patients both in Australia and around the world."
About Little Green Pharma (www.lgpharma.com.au)
Little Green Pharma is a private entity and one of the few companies in Australia with both a licence and permit to cultivate and produce Medicinal Cannabis. The harvesting of their crop marks the first time Medicinal Cannabis has been cultivated in Western Australia and is most likely the first crop for commercial use in Australia.
About LGC (www.lgc-capital.com)
LGC Capital Ltd. is a Canadian incorporated public company listed on the TSX Venture Exchange (TSXV: LG). LGC's objective is to become a diversified business group with core business divisions that provide shareholders with exposure to a diverse range of businesses, products and services with an emphasis on significant investments in global medical cannabis sector.
Information Relating to Little Green Pharma
All information contained in this press release relating to Little Green Pharma has been provided to LGC by Little Green Pharma. LGC has relied upon this information without having made independent inquiries as to its accuracy or completeness and assumes no responsibility for any inaccuracy or incompleteness of such information.
This press release may contain forward-looking statements with respect to LGC Capital Ltd. ("LGC") and Habi Pharma Pty Ltd ("Trading as Little Green Pharma"), and their respective operations, strategy, investments, financial performance and condition. These statements generally can be identified by use of forward- looking words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations. The actual results and performance of LGC and Little Green Pharma could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition, government regulation and the factors described under "Risk Factors and Risk Management" in LGC's Management's Discussion and Analysis for the fiscal year ended September 30, 2017, as filed on SEDAR (www.sedar.com). The cautionary statements qualify all forward-looking statements attributable to LGC and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this press release and neither LGC nor Little Green Pharma has any obligation to update such statements, except to the extent required by applicable securities laws.
Caution Regarding Press Releases
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE LGC Capital Ltd
For further information: please contact: John McMullen, Chief Executive Officer, Tel.: (416) 803-0698, Email: [email protected]; London contact: Anthony Samaha, Chief Financial Officer, Tel.: +44 (0) 20 7440 0640; Investor Relations: Dave Burwell, The Howard Group Inc., Tel.: (403) 221-9015, Toll Free: 1-888-221-0915, Email: [email protected]